PEDIATRICS Vol. 53 No. 6 June 1974, pp. 877-883
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fitzhardinge, P. M.
Right arrow Articles by Ramsay, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fitzhardinge, P. M.
Right arrow Articles by Ramsay, M.

Sequelae of Early Steroid Administration to the Newborn Infant

Pamela M. Fitzhardinge M.D.1, Abraham Eisen M.D.1, Christine Lejtenyi M.D.1, Katherine Metrakos M.D.1, and Maria Ramsay M.Sc.1

1 Department of Pediatrics, McGill University, Montreal

Twelve infants received hydrocortisone intravenously in the first 24 hours of life as therapy for RDS. They were paired with 12 similar infants who received a lactose placebo. Comparison follow-up studies were done on the two groups for one year and showed no difference in rate of growth or in ultimate size at 1 year of age. Steroid therapy was not associated with an increased rate of infection. Tests for immune competence were normal at one year in both groups. Infants who received the steroid tended to have a slightly increased incidence of gross neurological and electroencephalographic abnormalities. The developmental quotient was normal in both groups although subtests showed a significant lowering of the gross motor development in the study group.

Submitted on August 6, 1973
Accepted on December 20, 1973




This article has been cited by other articles:


Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
K J Rademaker, L S de Vries, C S P M Uiterwaal, F Groenendaal, D E Grobbee, and F van Bel
Postnatal hydrocortisone treatment for chronic lung disease in the preterm newborn and long-term neurodevelopmental follow-up
Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2008; 93(1): F58 - F63.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
L. W. Doyle, H. L. Halliday, R. A. Ehrenkranz, P. G. Davis, and J. C. Sinclair
Impact of Postnatal Systemic Corticosteroids on Mortality and Cerebral Palsy in Preterm Infants: Effect Modification by Risk for Chronic Lung Disease
Pediatrics, March 1, 2005; 115(3): 655 - 661.
[Abstract] [Full Text] [PDF]

Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
N. A. Parikh, R. G. Locke, A. Chidekel, K. H. Leef, J. Emberger, D. A. Paul, and J. L. Stefano
Effect of Inhaled Corticosteroids on Markers of Pulmonary Inflammation and Lung Maturation in Preterm Infants With Evolving Chronic Lung Disease
J Am Osteopath Assoc, March 1, 2004; 104(3): 114 - 120.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
K. J. Barrington
Hazards of systemic steroids for ventilator-dependent preterm infants: What would a parent want?
Can. Med. Assoc. J., July 1, 2001; 165(1): 33 - 34.
[Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
T. Bhuta and A. Ohlsson
Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease
Arch. Dis. Child. Fetal Neonatal Ed., July 1, 1998; 79(1): 26F - 33.
[Abstract] [Full Text]